The quarterly earnings season has arrived, causing dramatic swings in the market for various well-known companies. Yet, seasoned investors recognize that quarterly earnings reports should be seen through the lens of long-term investment strategies rather than as immediate market reactions. This approach is evident in the analysis of top stocks like Microsoft, Pfizer, NextEra Energy, Home Depot, and Fiverr International by Motley Fool contributors, as they discuss why these companies are solid long-term investments worth considering in May.
Image source: Getty Images.
Microsoft’s Unwavering Momentum
Daniel Foelber notes that Microsoft’s financial performance remains stellar, with significant growth driven by artificial intelligence and the remarkable expansion of its cloud business. The company’s ability to enhance overall performance by growing sales and margins across its segments is a testament to its financial prowess. In the recent quarter, Microsoft achieved a 21% year-over-year growth in Intelligent Cloud revenue and an impressive operating margin of 46.8% in this segment.
Metric | Q3 Fiscal 2023 | Q3 Fiscal 2024 | Change |
|---|---|---|---|
Productivity and Business Processes Revenue | $17.52 billion | $19.57 billion | 11.7% |
Data source: Microsoft.
Microsoft’s solid financial standing allows for substantial reinvestment in the business, acquisitions, and capital return programs. Despite its high valuation, Microsoft’s consistent growth and stability make it an attractive long-term investment option. With its robust business foundation and market advantages, the stock presents a compelling opportunity for investors in May.
Recognizing Pfizer’s Contrarian Appeal
Keith Speights makes a case for considering Pfizer as a compelling contrarian pick, acknowledging the challenges the pharmaceutical company faces. Pfizer’s declining revenue, earnings, and stock price are largely influenced by reduced demand for COVID-19 treatments. However, there is potential for a rebound in sales if Pfizer’s combination COVID-flu vaccine receives approval.
Pfizer’s concerns around patent expirations for key drugs pose another challenge, with estimated revenue impacts of approximately $17 billion by 2030 due to exclusivity losses. Despite these obstacles, Pfizer’s innovative product launches and expanded drug indications indicate resilience. The company’s track record suggests it has the capability to navigate through these hurdles successfully.